Loading company details...
Beta
Latest Form 4 (Aug 11, 2026): AH Bio Fund IV, L.P. (10% Owner): Conversion of 9,132,420 shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 11, 2026 | AH Bio Fund IV, L.P. | Conversion | 9,132,420 | n/a |
| Aug 11, 2026 | Erez Chimovits | Conversion | 9,132,420 | n/a |
| Aug 11, 2026 | ORBIMED ADVISORS LLC | Conversion | 9,132,420 | n/a |
| Aug 10, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Conversion | 7,420,091 | n/a |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. | Conversion | 9,132,420 | n/a |
| Aug 7, 2026 | James Paul Rickey, Chief Financial Officer | Purchase | 27,777 | $500.0K |
| Aug 7, 2026 | Tim Lohoff | Grant/Award | 30,000 | n/a |
| Aug 7, 2026 | Erez Chimovits | Grant/Award | 30,000 | n/a |
| Aug 7, 2026 | Christopher Viehbacher | Purchase | 83,333 | $1.50M |
| Aug 7, 2026 | David I. Malek | Purchase | 4,166 | $75.0K |